EUSOBI 2015: Breast Screening in Brazil
What are the particular challenges for implementing breast screening in Brazil?
The constraints are numerous, from difficulties obtaining information about population demographics to financial resources for implementation of screening and subsequent treatment of patients with cancer. Even in the programmes that do exist there is no active search for women nor control and data management, which characterise organised screening. The lack of demographic data impacts the search for woman who should be screened, and limits the ability to identify and locate patients diagnosed with mammographic abnormalities in need of other intervention, including cancer treatment. Regarding financial resources, there is a significant deficit of radiotherapy and chemotherapy in the country, not only in the poorest states, but also in large, wealthier cities. The delay in treatment limits the benefits of mammographic screening.
What screening technology is available in Brazil?
In Brazil there are two types of healthcare financing: one provided by the government serves 80% of the population. Private health insurance companies cover the remaining 20%. Conditions in these two systems are vastly different. In private services the patients have access to almost all modern technologies such as digital mammography (CR in many cases), ultrasound and MRI. Tomosynthesis is offered to a small group of the population and is not covered by health insurance companies. In the public health system conventional mammography is still quite common. These patients have access to ultrasound, but MRI and tomosynthesis are not widely implemented.
Women with dense breasts are not subject to a different screening programme. Because ultrasonography is an operator-dependent examination, there are no homogeneous quality standards followed throughout the country for it to be used as a screening method.
Is information about the importance of early detection of breast cancer readily available to women in Brazil?
Information concerning screening is widespread in the country, from
government, medical societies and NGOs. The disadvantages are not always discussed, either by the media or by the doctors who attend the women. There is also disagreement about the age of onset for mammographic screening between the government guidelines, which recommend mammography from 50 years of age, and medical societies that suggest beginning screening at age 40.
EUSOBI meets… Brazil
Published on : Mon, 21 Sep 2015
The SonoSite EDGE II is a high-resolution, all-digital, 9.0-pound (4.1 kg) ultrasound system with a 12.1in. LED full-bleed glass display. The Edge II boosts improvements in cardiac and abdominal image quality through DirectClear Technology and a new...
BioZorb® 3D Bioabsorbable Marker The BioZorb® is a 3D implantable marker that consists of a spiral, bioabsorbable framework embedded with 6 permanent, titanium clips designed to precisely mark your surgical excision site. Designed to improve outcomes...
We recognize that the best chance any patient has at getting better is a clinician at their bedside with all the right answers and the confidence to act. SonoSite education and training is the industry standard – no other point-of-care ultrasound manufacturer...
The Next Evolution in Ultrasound, designed for high expectations ARIETTA 850 ultrasound platform responds to high expectations to answer the ever increasing demands of medical professionals. ARIETTA 850’s fundamental performance has been refined...
Open high-field efficiency with patient-centric architecture OASIS™ is a new generation of MR systems, providing a high degree of diagnostic confidence and extraordinary patient comfort. With this unique scanner, Hitachi combines best high-field performance...